Anavex Life Sciences Corporation (AVXL) Quote

AVXL heading toward the high of the day, today!!!

Let’s make AVXL close at or very near the high of the day, today!!!

Good luck and GOD bless,

You claim not to be a pumper but you tell people to BUY, BUY, BUY AVXL and make wild predictions for GREAT, ABSOLUTELY GREAT, and HUGE news day in and day out, week in and week out, month in and month out, year in and year out. If the whole thing wasn't so pathetic it would be funny. You are fooling no one.

Here's the truth: Missling is and has been an unmitigated disaster for shareholders as well as for patients desperately in need of new therapies. He is among the worst CEOs in the history of biopharma. For a hundred good reasons he gets no respect from serious biotech investors. He needs to be replaced.

We won't.

We'll see with the AD OLE and the schizo POC.

AVXL is already running somewhat late with the AD OLE data. I'll be very surprised and pleased if AVXL releases that data in September.

How long does it take to analyze data?


In the case of AVXL, specifically the Phase 2b/III and Rett EXCELLENCE trials, it takes a lot more time than industry standard to report out trial data if you missed your primary endpoints and had to take extra time to data mine the results in an effort to find other substitutes to attempt to fix the hole in the dam.

we may even close green today.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

Nice. A profile created today for the sole purpose of neutralizing the threat of George. lol

Profit or return Steady?
Friday cocktails already so I don’t want to do the math.
Guessing it is your time premium inflection?

Subluxed, YES!!!

Going to be one hell of a close!!!

Please, post more often.

Good luck and GOD bless,

In general I am more inclined toward user fees and use tax rather than Income tax.
I already likely pay more sales tax than many two earner families pay the IRS.


Perhaps some of those purchases find a barter economy or similar, but....if I want it I’ll buy it.

Hey Georgie,
Only 4,500,000 more shares today to get to your 5 million share prediction. 2 more hours to go. Going to be one hell of a close.

VERY VERY FEW PEOPLE ARE SELLING SHARES OF AVXL TODAY!!!

That is very good!!!

DO NOT SELL AVXL SHARES TODAY!!!

We want the share price to close at or very near the high of the day today!!!

Good luck and GOD bless,

Sold a few shares and rolled that money into Jan 26 $10 options. My modeling shows that above a $14.73 SP the profit on the options is higher.

The SHORT SQUEEZE for AVXL stock could start VERY SOON actually any day now and last for days and possibly weeks!!!

Good luck and GOD bless,

The article reaches people to create awareness of Anavex. That is a good thing. It doesn't have to be analysis by the best in the world to be helpful. If it was a slam job by AF would that make you happier?

My state's DMV is 90% funded by DL and vehicle registration fees. Does that mean that it is coopted by the driving public?

The FDA charges a user fee for services i.e. the costs of evaluating a drug application. The fee is paid up front. It is not contingent on approval.

It's not like BP can take their business elsewhere if they don't like the service or results from the FDA.

The FDA is the gateway to the US market which is one of the largest and most lucrative drug consuming markets in the world.

IMHO the argument that the FDA is corrupt because it charges user fees that make up 70% of its budget is bogus.

If you want the AVXL shorters, bashers and FUDsters to lose, then BUY, BUY, BUY AVXL this afternoon!!!

Good luck and GOD bless,

A Very-extremely Impressive list-plan...thanks....MANY-happy folks-families ...This will take guts and brains to do...BEST TO ALL.

There are a lot of catalysts on the near term horizon to cause a jump in the AVXL stock price!!!

See sliide/page number 14 in the following September 2024 corporate presentation

https://www.anavex.com/_files/ugd/79bcf7_e5426a3b0863470aacd26f27e5fc4ae3.pdf

Good luck and GOD bless,

frrol: here's Missling's Definition for OLE:

Often Late Everytime

Well if they are all so much better what are you here??

ANVS and BIVI have fewer than 15 employees, yet they were still able to provide data relatively faster than Anavex. ANVS even put out a press release explaining why their data was delayed—something you'd never get from TGD. SAVA, with around 30 employees, is expected to release their Phase 3 results on schedule, according to industry norms. Anavex has mishandled every trial because of the CEO, who has no sense of time or urgency.

How many statisticians does it take to screw in a light bulb? kinda thing. But I guess if 87,000 employees each deal with say ten numbers, then things could go faster until their results gets to the guy/girl that have to quality check and assemble them into a useful conclusion.

Expect AVXL to close at or near the low of the day on light selling volume. Clearly there is no anticipation of significant near-term news.

Keep trying. Maybe there are still a few suckers out there who don’t know any better.

I’ll repeat what I said earlier. This is just another lame excuse to let Missling off the hook. First of all, the 87,000 employees at Sanofi are not all working on data analysis. Only a tiny fraction are involved. Second, with $140-$150 million in cash, Missling can well afford to hire however many consultants he needs to get things done in a timely manner, especially when it comes to Anavex’s most advanced program. There is overwhelming evidence that he does things on the cheap while hoarding cash for no apparent reason. You get what you pay for.

Expect approximately 5 million shares of AVXL stock to be bought by institutional investors at the close of trading today in anticipation of price catalysts next quarter!!!

Good luck and GOD bless,

The funny thing is that the WGTers never learn. They are either old and sick and therefore desperate for an effective new treatment or they simply cannot admit to the possibility of being wrong.

You are wondering if a company with 87,000 employees might be faster than one with 40?

The catalysts list is a joke; it’s been the same since 2020. Recently, TGD has been talking too much about Amazon—it seems like he wants to open a vitamin store on Amazon. He want to sell candies and gummies.

The same thing has been said every year for a decade. It never happens. Missling can’t get anything done in the time frames he himself puts out there publicly. Shorts have made fortunes because of it while longs have bled. There’s no evidence anything has changed or will change.

Keep trying. Maybe you’ll find a few new suckers.

There are a lot of catalysts on the near term horizon to cause a jump in the AVXL stock price!!!

See sliide/page number 14 in the following September 2024 corporate presentation

https://www.anavex.com/_files/ugd/79bcf7_e5426a3b0863470aacd26f27e5fc4ae3.pdf

Good luck and GOD bless,

Misleading keep talking about equity in healthcare and distributing pills on Amazon, but he doesn’t understand that the first step in that journey is starting the trial, completing it on time, getting result out in 2-3 weeks, and then filing the NDA for approval. I think he’s a psychopath, guy is over his head.

Indeed an item to watch.

For those not aware of the connection, karXT is a muscarinic modulator targeted toward schizophrenia and Alzheimer's agitation, while, Anavex's 3-71 is also targeted toward schizophrenia and is a S1R and muscarinic modulator. Muscarinic sites appear to be valid targets but thus far muscarinic modulators seem prone to side effects. karXT is a combo drug to mitigate side effects and 3-71 is a whole new compound.

WGT should be happy with this bot, per report fair market value is $590

Is there any statistically significant evidence that shows statistical analysis is easier and quicker for companies with a BP large mcap vs. one the size of that Anavex have?

Surely an Ex-FDA head of bio-statistics should amply make up for BP mcap, especially with a trial 6 times smaller and likely using the same or similar software for the calculations.

But bot articles can be really nice and comfy.

It’s bot analysis, not real analysis.

Positive article this morning: Simply Wall Street

https://finance.yahoo.com/news/anavex-life-sciences-corp-nasdaq-123410093.html

Simply Wall St.
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?
editorial-team@simplywallst.com (Simply Wall St)
Fri, Sep 20, 2024, 5:34 AM PDT

We feel now is a pretty good time to analyse Anavex Life Sciences Corp.'s (NASDAQ:AVXL) business as it appears the company may be on the cusp of a considerable accomplishment. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.
The US$466m market-cap company posted a loss in its most recent financial year of US$48m and a latest trailing-twelve-month loss of US$42m shrinking the gap between loss and breakeven. The most pressing concern for investors is Anavex Life Sciences' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

According to the 3 industry analysts covering Anavex Life Sciences, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$80m in 2025. The company is therefore projected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 61% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Given this is a high-level overview, we won’t go into details of Anavex Life Sciences' upcoming projects, however, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we’d like to point out is that Anavex Life Sciences has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:
This article is not intended to be a comprehensive analysis on Anavex Life Sciences, so if you are interested in understanding the company at a deeper level, take a look at Anavex Life Sciences' company page on Simply Wall St. We've also put together a list of important aspects you should further research:

Valuation: What is Anavex Life Sciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Anavex Life Sciences is currently mispriced by the market.
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Anavex Life Sciences’s board and the CEO’s background.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Just another schitty day, schitty week, schitty month, schitty year, schitty decade. Nothing ever changes - other than the stock sinking toward the gutter.

Lack of resources vs. Sanofi... I'll add this excuse to my long list of excuses to let Missling off the hook.

Anavex has around $140-$150 million in cash. They can well afford to spend more money on external resources on their most important programs in order to get the job done in a timely manner.

Lack of resources is nothing more than another lame excuse.

Missling is cheap. He does everything on the cheap while hoarding cash for no good reason.

I didn't realize that Missling had Sanofi's level of resources and expertise.

Well Sanofi have an $146 billion market cap.
Chat GPT estimated around early to mid-Sept for when OLE data should be released based on 96 week OLE trial with company of around 40 employees with final patient finishing June 14th so perhaps mildly behind but not that bad as of yet.

He's always talked a 'good game', and a bit of a bull s'er. BS walks with regulators. But we've got a good case if they're feeling particularly aggressive and receptive with AD.

We've clearly had some problematic CROs, though of course that doesn't excuse management, who selects and manages them. And we've augmented our inhouse biostat function, so that should speed things up. We'll see with the AD OLE and the schizo POC.

I took his comment as inferring hedging.
Then again I use other methods to balance my aggressive nature
with conservative goals.

Your bot is working overtime George.
It does appear to need extra "teaching" to improve the relevance of your emojis.

already have a bit more allocated to AVXL than I should

The first step to understanding a problem is acknowledging it.
Has served me well over time, even if not ALWAYS given the adherence it deserves.

How long does it take to analyze data?

I'm at a large conference and Sanofi just presented three phase 3 trials on tolebrutinib - 2 in RRMS and 1 in SPMS ---- close to 3000 patients overall. The 2 phase 3 trials had the last study visit 6 weeks ago, and then had a shared database lock 4 weeks ago. They analyzed the primary and key secondary endpoints, checked and rechecked, wrote a PR for the initial PR only 2 weeks later and then presented all three trials at ECTRIMS today. They plan to submit to the FDA for progressive MS by the end of the year. Missling is not a serious manager.

Some bold / confident statements from Missling - hope they will pass the regulatory reality check.

FDA funded 70% by BP. They are compromised. imo
SEC?

People want access to Blarcamesine now.

But there is an 83% chance of EMA approval. What could possibly go wrong?